SIENTRA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.065 USD | -1.52% |
|
-18.55% | -89.34% |
| Apr. 15 | Reorganization Plan and Disclosure Statement Filed by Sientra, Inc. | CI |
| Apr. 11 | North American Morning Briefing : Stock Futures -2- | DJ |
Financials (USD)
| Sales 2021 | 80.68M | Sales 2022 | 90.55M | Capitalization | 20.49M |
|---|---|---|---|---|---|
| Net income 2021 | -62M | Net income 2022 | -73M | EV / Sales 2021 | 2.89 x |
| Net Debt 2021 | 20.17M | Net Debt 2022 | 36.68M | EV / Sales 2022 | 0.63 x |
| P/E ratio 2021 |
-3.35
x | P/E ratio 2022 |
-0.2
x | Employees | 304 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 90.42% |
More Fundamentals
* Assessed data
More news
Latest transcript on Sientra, Inc.
More recommendations
| 1 day | -1.52% | ||
| 1 week | -18.55% | ||
| Current month | -72.34% | ||
| 1 month | -38.10% | ||
| 3 months | -89.00% | ||
| 6 months | -95.36% | ||
| Current year | -89.34% |
1 week
0.05
0.09
1 month
0.050.35
Current year
0.051.15
1 year
0.054.94
3 years
0.0591.40
5 years
0.0597.10
10 years
0.05267.90
| Managers | Title | Age | Since |
|---|---|---|---|
Ronald Menezes
CEO | Chief Executive Officer | 61 | 20-11-09 |
Andrew Schmidt
DFI | Director of Finance/CFO | 62 | 21-07-11 |
Denise Dajles
CTO | Chief Tech/Sci/R&D Officer | - | 21-05-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 62 | 17-02-05 | |
Alexander Casdin
BRD | Director/Board Member | 56 | 23-06-14 |
Mary Fisher
BRD | Director/Board Member | 62 | 18-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-22 | 0.065 | -1.52% | 229,436 |
| 24-04-19 | 0.066 | 0.00% | 19,668 |
| 24-04-18 | 0.066 | -18.56% | 2,874 |
| 24-04-17 | 0.081 | +43.18% | 33,322 |
| 24-04-16 | 0.0566 | -29.07% | 18,255 |
Delayed Quote OTC Markets, April 22, 2024 at 03:24 pm EDT
More quotes
Sientra, Inc. is a medical aesthetics company. The Company is engaged in transformative treatments and technologies focused on advancing plastic surgery. The Company provides medical aesthetics products to certified plastic surgeons and patients. It has developed a portfolio of products with technologically differentiated characteristics, supported by independent laboratory testing and strong clinical trial outcomes. The Company sells its breast implants, breast tissue expanders, and fat transfer system for reconstruction procedures predominantly to hospitals and surgery centers, and its BIOCORNEUM scar management products to plastic surgeons, dermatologists and other specialties. The Company's brands also include Sientra, Sientra Platinum20, Sientra Full Circle, Sientra Smooth, Sientra Teardrop, AlloX, AlloX2, Anatomical Controlled, BIOCORNEUM, Curve, Dermaspan, Luxe, Softspan, Silishield, AuraClens and Viality.
Calendar
2024-05-07
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -89.34% | 777K | |
| -2.73% | 186B | |
| -2.20% | 107B | |
| -4.08% | 67.57B | |
| +5.99% | 50.7B | |
| +15.32% | 47.2B | |
| -0.45% | 39.72B | |
| +6.60% | 27.48B | |
| -1.11% | 25.65B | |
| -0.76% | 24.82B |
- Stock Market
- Equities
- SIEN Stock
